磷酸依米他韦联合索磷布韦治疗基因1型非肝硬化慢性丙型肝炎病毒感染者的真实世界研究

肝脏 ›› 2026, Vol. 31 ›› Issue (8): 1133-1136.

磷酸依米他韦联合索磷布韦治疗基因1型非肝硬化慢性丙型肝炎病毒感染者的真实世界研究

阮军, 寇国先, 蒲昳昀, 杨庆, 尹恒

621000 绵阳电子科技大学医学院附属绵阳医院,绵阳市中心医院感染科(阮军,寇国先,蒲昳昀,杨庆),肾病科(尹恒)

收稿日期:2025-09-15 出版日期:2026-08-31 发布日期:2026-09-28
通讯作者: 尹恒,Email:45864791@qq.com
基金资助:
绵阳市中心医院2022年度孵化课题(2022FH014)

A real-world study of emitasvir phosphate combined with sofosbuvir in the treatment of patients with genotype 1 non-cirrhotic chronic hepatitis C virus infection

Ruan Jun¹, Kou Guoxian¹, Pu Yiyun¹, Yang Qing¹, Yin Heng²

1. Department of Infectious Diseases, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang 621000, China;
2. Department of Nephrology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang 621000, China

Received:2025-09-15 Online:2026-08-31 Published:2026-09-28
Contact: Yin Heng, Email: 45864791@qq.com

摘要/Abstract

摘要： 目的评估磷酸依米他韦联合索磷布韦治疗基因1型非肝硬化慢性丙型肝炎病毒(HCV)感染者的临床效果和安全性。方法选择2024年1月至2024年12月绵阳市中心医院诊治的81例基因1型初治的非肝硬化慢性HCV感染者为研究对象,予以磷酸依米他韦联合索磷布韦治疗12周。观察治疗结束后12周时持续病毒学应答(SVR12)、治疗4周时快速病毒学应答、治疗12周时病毒学应答及不良反应发生情况。结果 81例基因1型初治的非肝硬化慢性HCV感染者多为中老年已婚男性(46例,56.8%),多来自经济发展水平较低的乡镇地区(67例,82.7%),HCV感染途径主要是经血液接触传播(69例,85.2%),HCV基因型最常见的是基因1b型(78例,96.3%)。所有患者均完成了磷酸依米他韦+索磷布韦的12周联合治疗方案,治疗4周时快速病毒学应答率为96.3%(78/81),治疗12周时病毒学应答率为100%(81/81),治疗结束后SVR12率为100%(81/81)。在治疗期间未出现严重不良反应,但有13例患者发生轻度不良反应。结论磷酸依米他韦联合索磷布韦12周方案具有良好的有效性和安全性,可以作为基因1型非肝硬化慢性HCV感染者的一种有效治疗方案,值得临床进一步推广应用。

关键词: 丙型肝炎病毒, 磷酸依米他韦, 索磷布韦, 基因1型, 真实世界研究

Abstract: Objective To evaluate the clinical efficacy and safety of emitasvir phosphate combined with sofosbuvir in the treatment of patients with genotype 1 non-cirrhotic chronic hepatitis C virus (HCV) infection. Methods A total of 81 patients with genotype 1 non-cirrhotic chronic HCV infection who were initially treated in Mianyang Central Hospital from January 2024 to December 2024 were selected as the study subjects and were treated with emitasvir phosphate combined with sofosbuvir for 12 weeks. The sustained virological response at 12 weeks (SVR12) after the end of treatment, rapid virological response at 4 weeks after treatment, virological response at 12 weeks after treatment and the occurrence of adverse reactions were observed. Results Most of the 81 patients with genotype 1 non-cirrhotic chronic HCV infection who were initially treated were middle-aged and elderly married men (46 cases, 56.8%), mostly from rural areas with low economic development level (67 cases, 82.7%). HCV infection was mainly transmitted through blood contact (69 cases, 85.2%), and the most common HCV genotype was genotype 1b (78 cases, 96.3%). All patients completed the 12-week combination regimen of emitasvir phosphate plus sofosbuvir, with a 4-week rapid virologic response rate of 96.3% (78/81) and a 100% (81/81) virologic response rate at 12 weeks after treatment. The SVR12 after the end of treatment was 100% (81/81). There were no serious adverse reactions during the treatment period, but 13 patients had mild adverse reactions. Conclusion The 12-week regimen of emitasvir phosphate combined with sofosbuvir has good efficacy and safety, and can be used as an effective treatment for patients with genotype 1 non-cirrhotic chronic HCV infection, which is worthy of further clinical application.

Key words: Hepatitis C virus, Emitasvir phosphate, Sofosbuvir, Genotype 1, Real-world study

阮军, 寇国先, 蒲昳昀, 杨庆, 尹恒. 磷酸依米他韦联合索磷布韦治疗基因1型非肝硬化慢性丙型肝炎病毒感染者的真实世界研究[J]. 肝脏, 2026, 31(8): 1133-1136.

Ruan Jun, Kou Guoxian, Pu Yiyun, Yang Qing, Yin Heng. A real-world study of emitasvir phosphate combined with sofosbuvir in the treatment of patients with genotype 1 non-cirrhotic chronic hepatitis C virus infection[J]. Chinese Hepatolgy, 2026, 31(8): 1133-1136.

/ 推荐

参考文献

[1] 中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南(2022年版)[J].中华肝脏病杂志,2022,30(12):1332-1348.
[2] World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016—2021: actions for impact[M]. Geneva: World Health Organization, 2021.
[3] 中华预防医学会医院感染控制分会,中华医学会感染病学分会,中华预防医学会感染性疾病防控分会.中国丙型病毒性肝炎医院感染防控指南(2021年版)[J].中国感染控制杂志,2021,20(6):487-493.
[4] 李健,庞琳,王晓春,等.中国丙型肝炎防治进展与展望[J].中国艾滋病性病,2022,28(7):761-765.
[5] Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study[J]. Lancet Gastroenterol Hepatol, 2022, 7(5):396-415.
[6] 李月荣,黄景豪,应若素.我国丙型病毒性肝炎流行现况和防治进展[J].广州医科大学学报,2024,52(5):68-73.
[7] Kang L, Pan J, Wu J, et al. Anti HBV drugs: progress, unmet needs, and new hope[J]. Viruses, 2015, 7(9):4960-4977.
[8] Mei X, Lu H. Prevalence, diagnosis, and treatment of hepatitis C in Mainland China[J]. Glob Health Med, 2021, 3(5):270-275.
[9] Guntipalli P, Pakala R, Kumari Gara S, et al. Worldwide prevalence,genotype distribution and management of hepatitis C[J]. Acta Gastroenterol Belg, 2021, 84(4):637-656.
[10] 冉锡萍,蔡大川.直接抗病毒药物在丙型肝炎肝硬化患者中的应用进展[J].临床肝胆病杂志,2024,40(8):1682-1687.
[11] Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection[J]. N Engl J Med, 2013, 368(20):1878-1887.
[12] 罗碧芬,金晶兰,饶慧瑛,等.磷酸依米他韦联合索磷布韦治疗慢性丙型肝炎病毒感染的有效性和安全性[J].中华传染病杂志,2019,37(7):420-429.
[13] Rao H, Yang X, Tan Y, et al. Efficacy and safety of all-oral emitasvir and sofosbuvir in patients with genotype 1b HCV infections with cirrhosis[J]. J Clin Transl Hepatol, 2020, 8(3):255-261.
[14] 王晓丽,熊军,杨晓玲.绵阳市涪城区2013-2022年丙型病毒性肝炎流行特征分析[J].传染病信息,2023,36(5):433-444.
[15] Wei L, Jia J, Wang F, et al. Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: final results from the randomized C-CORAL study[J]. J Gastroenterol Hepatol, 2019,34(1):12-21.
[16] Wei L, Xie Q, Hou J, et al. Ledipasvir/sofosbuvir for treatment-naÏve and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study[J]. Hepatol Int, 2018, 12(2):126-132.
[17] 赵友飞,徐亮,宓余强.直接抗病毒药物治疗慢性丙型肝硬化的研究进展[J].中华肝脏病杂志,2024,32(1):87-90.
[18] 许姗姗,仇丽霞,柳雅立,等.丙型肝炎持续病毒学应答后肝癌发生的危险因素及预测模型[J].临床肝胆病杂志,2024,40(6):1259-1263.